http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109265561-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate | 2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-109265561-B |
| titleOfInvention | anti-EGFRv III safe chimeric antigen receptor, preparation method thereof, NK cell modified by same and application |
| abstract | The invention belongs to an anti-EGFRvIII safe chimeric antigen receptor, a preparation method thereof, an NK cell modified by the anti-EGFRvIII safe chimeric antigen receptor and an application, wherein the anti-EGFRvIII safe chimeric antigen receptor comprises a CD8leader nucleic acid sequence, an EGFRvIII scFv nucleic acid sequence, a CD8 alpha nucleic acid sequence, an NKG2D nucleic acid sequence, a 2B4 nucleic acid sequence, a CD3 zeta nucleic acid sequence, a self-cleavage polypeptide T2A nucleic acid sequence and an RQR8 nucleic acid sequence. The anti-EGFRv III safe chimeric antigen receptor provided by the invention can reduce serious toxic and side effects caused by excessive activity or uncontrolled activity after the chimeric antigen receptor is infused into a body. |
| priorityDate | 2018-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 65.